Clinical Trials on Orthomyxoviridae-Infektionen

Total 2027 results

National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

Influenza, Human

United States
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

Influenza

United States
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Influenza

Brazil
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Influenza

United States
Helmholtz Centre for Infection Research
Hannover Medical School; Clinical Research Center, Hannover, Germany; Hannover...

Completed

Influenza Vaccination Among the Elderly Individuals

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Influenza
Autoimmune Technologies, LLC
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...

Influenza, Human

United States
Novartis Vaccines
Novartis

Completed

Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

Influenza

United States, Mexico
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Influenza

United States
Vaxart

Completed

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Novartis
Novartis Vaccines

Withdrawn

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Antiviral DAS-181-F04 in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine

Influenza

Czech Republic
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Influenza

Belgium, Poland, France, Germany, Italy, Spain
Dalhousie University
PHAC/CIHR Influenza Research Network

Completed

Influenza Vaccine Safety and Effectiveness in Healthcare Providers

Influenza
McMaster University
University of Calgary; University of Saskatchewan

Unknown

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Influenza

Canada
GlaxoSmithKline

Completed

Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States

Influenza

United States
Abbott

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Australia
Novartis Vaccines

Completed

Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008

Influenza

United Kingdom
London School of Hygiene and Tropical Medicine
Wellcome Trust; National Health Service, United Kingdom

Completed

Text Messaging Reminders for Influenza Vaccine in Primary Care (TXT4FLUJAB)

Influenza

United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

Influenza

United States
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older

Influenza
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Seqirus

Completed

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Children

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Elderly Participants

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine

Influenza

Australia
American Pharmacists Association Foundation

Completed

Project IMPACT Immunizations (IMProving America's Communities Together)

Influenza

United States
University of California, Los Angeles
J. Craig Venter Institute

Completed

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

Influenza

United States
Butantan Institute

Completed

Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine (FLU-01-IB)

Influenza

Brazil
Butantan Institute

Completed

Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB (FLU-02-IB)

Influenza

Brazil
GlaxoSmithKline

Withdrawn

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Influenza
Hoffmann-La Roche

Completed

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

Influenza

Belgium, Israel, Italy, Spain, United States, Germany, Canada, France, Estonia, Poland, Hungary, Lithuania, United Kingdom, Czech Republic
Sanofi Pasteur, a Sanofi Company

Completed

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Influenza

United States
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Hvivo

Completed

Influenza Challenge Study in Healthy Volunteers

Influenza

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

Influenza

United States, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

Influenza | Orthomyxoviridae Infections

United States
Visterra, Inc.

Completed

Influenza Challenge Study of VIS410 in Healthy Volunteers

Influenza

Belgium

3

Subscribe